By elucidating the molecular mechanisms underlying HSP-mediated protection in NAFLD, this article aims to pave the way for the development of targeted therapies for this prevalent liver disorder. The gene discussed is HSP90B2P; the disease is metabolic dysfunction-associated steatotic liver disease.